Pereiti prie turinio

Update on the Phase II GENERATION HD2 study

Roche has announced the continuation of the GENERATION HD2 Phase II clinical trial evaluating tominersen in individuals with early signs of Huntington’s disease. Following an interim analysis by an independent committee, no […]

EHA Conference 2025

We are excited to announce that the European Huntington Association will be organising its 5th Biannual Conference in Bucharest, Romania, from September 25th-28th, 2025. “Shaping our Future Together, We are the Change!” encapsulates the spirit […]

Žvilgsnis į 2025 m. HDYO kongresą

The HDYO Congress 2025 brought together young people, families, researchers, and professionals from around the world for an unforgettable event dedicated to the Huntington’s Disease community. Over three inspiring days, […]

"SOM Biotech" paskelbė 2b fazės tyrimo rezultatus

SOM Biotech presents the Phase 2b study results with SOM3355 demonstrating a unique profile with robust improvements of chorea in Huntington’s Disease Patients and a safe profile with no somnolence, […]

lt_LTLithuanian